Partnership
Fluicell is a Swedish biotech company that has developed a unique open volume microfluidic technology with multiple applications across drug development and regenerative medicine. Fluicell was founded in 2012 based on research at Chalmers University of Technology and has provided innovative research solutions to multiple research institutions and pharmaceutical companies, significantly contributing to many important scientific breakthroughs.
On behalf of Ambusol, Fluicell is developing a new type of catheter technology that will be part of Ambusol’s approach for cancer treatment. The new device is designed to be able to deliver cancer therapeutics directly to solid tumors with high precision and simultaneously remove cell debris and other waste materials. Together with Ambusol’s therapeutic solutions, the new catheter technology constitutes a new approach to target forms of cancer that today lack adequate treatment.
Read more about Fluicell on fluicell.com